Last week, Jennifer Lawrence and other celebrities had indiscrete photos stolen and distributed across the Internet. It’s speculated that their accounts were accessed by a “brute force” attack—which can only be successful if their passwords were weak.
Weak passwords are a risk for businesses, too. Verizon found that 76% of all network intrusions exploit weak or stolen passwords.
To protect critical data, every employee at every business must use strong passwords (which have no fewer than 12 characters). But with an average of 14.3 apps per business, users are likely to take shortcuts by creating passwords that are easy to memorize – and easy to crack.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7286151-intermedia-appid-single-sign-on-passwords-one-click-access/
Watch this video by NRMA for top tips on motorcycle lane filtering, to keep you safe and moving on NSW roads.
NRMA offer comprehensive motorbike insurance, providing you with cover for your bike against any accidental damage, collision or crashes.
In NSW, lane filtering became legal as of the 1st July 2014. In heavy traffic on multi-lane roads, riders often filter between the lanes. It can be an efficient way to road your motorcycle when done correctly.
1. When you are lane-filtering look out for drivers on both sides.
2. Watch for body language as an indication that they are about to change lanes.
3. Get your speed right. While it may be legal to travel at 30km an hour, it may not be safe to do so.
4. Never ride to the left of a vehicle; it puts you at risk of a collision with a vehicle entering a driveway.
5. Be aware of circumstances where it is still illegal to filter lanes, this includes active school zones.
Accidents happen and if you ride a motorbike or scooter then a motorcycle insurance policy could cover someone else’s property and your motorcycle, should you have an accident.
http://www.nrma.com.au/motorcycle-insurance
Meijer announced today it is launching its new Consumer Drug Take-Back Program by installing secure in-store kiosks designed to help customers safely and properly dispose of unused or expired prescription drugs at no cost. Customers can find the easily identifiable kiosks in the pharmacy area in all 241 Meijer supercenters across the Midwest.
“Meijer is thrilled to be one of the first in our industry to provide a secure and convenient prescription drug take-back program at all stores in the communities we serve,” said Jason Beauch, Vice President of Meijer Pharmacy. “The Meijer Drug Take-Back Program allows our customers to remove the risk of an unforeseen accident occurring with expired or unused medications, while enabling them to properly dispose prescription drugs and reducing the possibility of creating a public health hazard.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8497051-meijer-consumer-drug-take-back-program/
Exact Sciences Corp. (NASDAQ: EXAS) announced today that the U.S. Food and Drug Administration (FDA) has approved Cologuard, the company’s noninvasive, stool DNA colorectal cancer screening test. Cologuard is the first noninvasive screening test for colorectal cancer that analyzes both stool DNA and blood biomarkers and has been proven to find 92 percent of cancers and 69 percent of the most advanced precancerous polyps in average risk patients. Cologuard, which is available through healthcare providers, offers people 50 and older at average risk for colorectal cancer an easy–to–use screening test they can do in the privacy of their own home.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7092251-fda-approve-s-exact-sciences-cologuard-screening-test-colorectal-cancer/
Companies in every part of the nation sponsor tax-qualified benefit plans to attract and retain high quality employees. The plans are designed to offer employees tax relief as they build up their retirement through 401k plans or to buy medical and dental type benefits. However, according to EisnerAmper's Pension Services Group, tax relief that benefits both the employer and the plan participants is at risk of being lost if plan sponsors fail to follow basic qualification requirements by maintaining effective internal control structures over their plans.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7461932-eisneramper-employee-benefits/
LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today recognizes that more than one million people in the United States with drug-resistant epilepsy continue to be treated unsuccessfully with drugs, despite the proven effectiveness of non-drug treatment options. LivaNova’s VNS Therapy®, for example, is a medical device treatment specifically designed for people with drug-resistant epilepsy that is already used by more than 85,000 people around the world.
One in three people with epilepsy has the type that is not well controlled with drugs, called drug-resistant epilepsy. For those people, prescribing more medicine is usually not the most effective option. In fact, research shows that if you haven’t found seizure freedom after your first two drugs, there is a 95 percent chance that no drug or combination of drugs will result in seizure freedom.
“Despite what we know about drug-resistant epilepsy, the majority of people affected by this condition will continue to be prescribed additional medications instead of being evaluated for surgery or seen in a specialized epilepsy facility,” said Jason Richey, president of LivaNova’s U.S. Region and general manager of the Neuromodulation Business Franchise. “This treatment gap means over one million individuals in the U.S. with undertreated epilepsy remain at risk for dangerous side effects of continued seizures, including injury, depression, memory issues and death.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7966451-livanova-vns-therapy-epilepsy/
New data from a school asthma management program, “Building Bridges for Asthma Care,” presented today at the American Thoracic Society 2015 International Conference, show a significant decrease in school absenteeism among children with asthma from inner-city schools who were enrolled in the program. Absences dropped 11.75 percent among children enrolled in Building Bridges, compared to an increase of 8.48 percent in children with asthma not in the program.
“Building Bridges for Asthma Care” is a school-based program designed to empower nurses in participating elementary schools to ensure that asthmatic children are identified and provided care according to the National Institute of Health’s clinical treatment guidelines. The objectives of the program are addressing the risk of health disparities and asthma-related absenteeism, as well as its related impact on academic achievement for inner city students.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7506851-gsk-building-bridges-for-asthma-care/
According to a recent survey, active adults aren’t slowing down. The survey found that 62 percent of adults ages 30-49 continue to work out as much – and with the same or more intensity – as they did in their 20s. More than half would like to ramp up their performance and do more of what they love, but are stopped by pain and the risk of injuries.
Massage Envy’s new, proprietary assisted stretching service, called Total Body Stretch, is designed to help people perform at their best, ease the muscle pain and tension that comes with activity, and resist injuries.
Developed for Massage Envy by an acclaimed chiropractor, massage therapist and ergonomist and performed by a stretching professional, the Total Body Stretch service is built around the company’s proprietary Streto Method, a sequence of 10 targeted stretches designed to increase flexibility, mobility and performance.
To view the multimedia release go to:
https://www.multivu.com/players/English/8133351-massage-envy-streto-total-body-stretch/
In order to succeed in today’s B2B sales world, salespeople must create buyer consensus among diverse customer stakeholders. Those who fail to do that risk falling victim to the status-quo – the minimal-risk, lowest-cost option – or worse, losing the deal altogether. The Challenger Customer: Selling to the Hidden Influencer Who Can Multiply Your Results from CEB (NYSE: CEB), a best practice insight and technology company, reveals that it isn’t just about how you engage, but who you engage within the customer organization that drives complex sales today.
“The ‘senior decision-maker’ no longer exists in B2B sales. That makes the most significant problem facing marketing and sales teams a buying problem, not a selling problem. Organizations need to shift their focus from making the sale to understanding buyer groups – and who among them really shapes decisions,” said co-author Brent Adamson, executive advisor at CEB. “Our research shows that the one thing that matters most to executives is whether or not a supplier has buy-in with the rest of the organization – NOT the supplier’s actual offering or solution.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7427252-ceb-the-challenger-customer/
New research from Carfax suggests that millions of people may be driving, buying, or selling potentially dangerous cars due to an unfixed recall. The company’s annual research on the issue shows more than 46 million cars nationwide have at least one safety recall that’s never been fixed. In fact, five million of them were bought and sold by potentially unsuspecting consumers in 2014.
One of the most alarming discoveries is that people driving or buying family-oriented vehicles – specifically minivans and SUVs – are most at risk. One in three minivans and one in five SUVs has an unfixed recall, according to Carfax.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7385551-carfax-unfixed-recall-data/
A ten-month clinical trial at Sentara Leigh Hospital in Norfolk, Virginia has determined that hard surfaces and linens infused with copper oxide compounds contributed to an 83% reduction in C-difficile and a 78% overall reduction in a host of multi-drug resistant organisms (MDROs) including C-diff, MRSA and VRE in a real-world clinical environment. These results occurred in a hospital with a robust protocol for managing infection risk certified by the health care accrediting body DNV-GL Healthcare.
The results of the trial were published in the peer-reviewed American Journal of Infection Control on Sept. 28, 2016 and will be presented at the annual conference of the Infectious Disease Society of America in New Orleans, Louisiana on October 27, 2016.
To view the multimedia release go to:
http://www.multivu.com/players/English/7955751-sentara-healthcare-infections-copper-clinical-trial/
The National Meningitis Association (NMA) today announced the launch of a new educational initiative in collaboration with Sanofi Pasteur, the vaccines division of Sanofi, about the importance of the Centers for Disease Control and Prevention’s (CDC’s) recommended second dose of the meningococcal meningitis vaccine (MenACWY) for adolescents at age 16. The 16 Vaccine (The16Vaccine.org) aims to educate parents about the importance of this critical second dose of MenACWY, which helps protect teens against meningococcal meningitis during the period when they are at increased risk.
To view the multimedia release go to:
https://www.multivu.com/players/English/8385951-national-meningitis-association-the-16-vaccine/
